300791.SZ
Sirio Pharma Co., Ltd.
SZSE · Consumer Defensive · C 制造业 · CN
CNY 16.98
+2.66%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.3B | 4.3B | 4.2B | 3.6B | 2.5B |
| Cost of Revenue | 3.0B | 3.0B | 2.9B | 2.5B | 1.7B |
| Gross Profit | 1.3B | 1.3B | 1.3B | 1.1B | 781.7M |
| Operating Expenses | |||||
| R&D Expense | 147.0M | 145.9M | 125.9M | 110.5M | 80.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 460.9M | 466.1M | 417.7M | 350.8M | 304.4M |
| Selling & Marketing Expense | 370.7M | 373.2M | 353.2M | 277.6M | 130.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.1B | 1.1B | 1.0B | 813.7M | 537.3M |
| Cost and Expenses | 4.1B | 4.1B | 3.9B | 3.3B | 2.3B |
| Operating Income (EBIT) | (3.6M) | 8.4M | 327.0M | 282.0M | 265.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (19.0M) | (5.9M) | 316.7M | 273.3M | 251.5M |
| Income Tax Expense | (24.8M) | (26.3M) | 34.6M | 33.0M | 39.2M |
| Bottom Line | |||||
| Net Income | 117.8M | 136.5M | 325.1M | 281.0M | 212.3M |
| Earnings from Cont. Ops | 5.8M | 20.4M | 282.0M | 240.3M | 212.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 117.8M | 136.5M | 325.1M | 281.0M | 212.3M |
| Per Share | |||||
| Basic EPS | CN¥0.39 | CN¥0.45 | CN¥1.07 | CN¥1.20 | CN¥1.18 |
| Diluted EPS | CN¥0.39 | CN¥0.45 | CN¥1.07 | CN¥1.20 | CN¥1.17 |
| Revenue Per Share | CN¥14.14 | CN¥13.95 | CN¥13.87 | CN¥15.28 | CN¥13.93 |
| Shares | |||||
| Basic Shares Outstanding | 304.9M | 305.6M | 303.7M | 234.4M | 180.0M |
| Diluted Shares Outstanding | 304.9M | 305.6M | 303.7M | 234.4M | 180.0M |
| Profitability Metrics | |||||
| EBITDA | — | 251.7M | 580.5M | 508.8M | 394.1M |
| D&A | — | 243.4M | 253.5M | 226.8M | 129.0M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026